Vor Bio announced that telitacicept significantly preserved kidney function in adults with IgA nephropathy over 104 weeks in the Phase 3 TELIGAN trial. The drug reduced the annual decline in kidney filtration rate by 5.1 mL/min/1.73 m²/year compared to placebo and lowered the risk of significant kidney function decline by up to 89%. Proteinuria reductions were sustained with a favorable safety profile, supporting telitacicept's potential as a durable treatment for this chronic kidney disease. The drug has conditional approval in China and is undergoing further global trials for autoimmune diseases.
Telitacicept's kidney function preservation data is presented here alongside Pluang's Health sector market snapshot. Of 150 priced Health-sector US stocks tradable on Pluang, 77 rose and 71 fell today. Notable movers include MRNA at USD 199.53 with a 1-day change of -18.83%, HRTX at USD 0.29 with -15.17%, and TWST at USD 134.33 with -9.92%, as of Oct 23, 2026 02:41 WIB.
Share-ify introduced the S.A.F.E. Score™, an AI-powered forecasting engine designed to enhance supplier risk intelligence within its food safety and compliance solutions. This tool analyzes diverse data such as audit results, recall history, and insp...
EquipmentShare, a major U.S. construction equipment rental and technology provider, will announce its fiscal third quarter 2026 financial results after market close on November 9, 2026. The company will host a conference call for investors and analys...
Atlantic American Corporation received a Nasdaq Staff Delisting Determination due to missing its 2025 annual and 2026 quarterly SEC reports by the extended October 12 deadline. The company has since filed the 2025 annual report and is working to subm...
Randstad reported revenue and earnings that exceeded expectations, driven by improving business trends and key labor markets. This positive performance signals momentum in the employment services sector. RBC Capital maintained a 'Sector Perform' rati...
MSC Industrial Supply reported strong Q4 results with revenue rising 10.3% year-over-year to about $1.08 billion, surpassing estimates. Adjusted earnings per share increased to $1.45 from $1.09, also beating expectations. Full-year sales grew 6.4% to...
